TY - JOUR
T1 - What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?
AU - Schön, Thomas
AU - Köser, Claudio Umberto
AU - Werngren, Jim
AU - Viveiros, Miguel
AU - Georghiou, Sophia
AU - Kahlmeter, Gunnar
AU - Giske, Christian
AU - Maurer, Florian
AU - Lina, Gerard
AU - Turnidge, John
AU - van Ingen, Jakko
AU - Jankovic, Mateja
AU - Goletti, Delia
AU - Cirillo, Daniela Maria
AU - Santin, Miguel
AU - Cambau, Emmanuelle
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Drug-resistant tuberculosis (TB) is estimated to account for approximately 30% of annual deaths due to antimicrobial resistance (AMR) [ 1 ]. This is mainly due to mortality of approximately 44% caused by multidrug-resistant (MDR) TB (defined by resistance to isoniazid and rifampicin) [ 2 ]. Therefore, accurately diagnosing AMR for TB is crucial not only to select the most effective regimen with the least side effects but also to minimize costs (e.g. the median cost to treat MDR-TB is $6430 compared with $973 for drug-susceptible TB) [ 2 ]. Owing to the slow growth rate of the Mycobacterium tuberculosis complex (MTBC), this is increasingly achieved using genotypic approaches [ 3 ]. However, phenotypic antimicrobial susceptibility testing (pAST) is still needed to correlate the presence of mutations and their phenotypic expression, especially for new anti-TB agents for which resistance mutations are unknown.
AB - Drug-resistant tuberculosis (TB) is estimated to account for approximately 30% of annual deaths due to antimicrobial resistance (AMR) [ 1 ]. This is mainly due to mortality of approximately 44% caused by multidrug-resistant (MDR) TB (defined by resistance to isoniazid and rifampicin) [ 2 ]. Therefore, accurately diagnosing AMR for TB is crucial not only to select the most effective regimen with the least side effects but also to minimize costs (e.g. the median cost to treat MDR-TB is $6430 compared with $973 for drug-susceptible TB) [ 2 ]. Owing to the slow growth rate of the Mycobacterium tuberculosis complex (MTBC), this is increasingly achieved using genotypic approaches [ 3 ]. However, phenotypic antimicrobial susceptibility testing (pAST) is still needed to correlate the presence of mutations and their phenotypic expression, especially for new anti-TB agents for which resistance mutations are unknown.
KW - Drug susceptibility testing
KW - EUCAST
KW - MDR
KW - MIC
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85090158085&partnerID=8YFLogxK
UR - https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30445-6/fulltext
U2 - 10.1016/j.cmi.2020.07.037
DO - 10.1016/j.cmi.2020.07.037
M3 - Comment/debate
C2 - 32768492
AN - SCOPUS:85090158085
SN - 1198-743X
VL - 26
SP - 1453
EP - 1455
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 11
ER -
